Pharma Pulse 3/18/24: Weight-Loss Drug Through Amazon, Overcoming Gender Inequities in Health Care & more


The latest news for pharma industry insiders.

Personalizing the Trial Experience for Diverse Populations

In this Applied Clinical Trials video interview, Julia Lakeland, Chief Product Officer, uMotif, discusses new technologies that can help personalize the clinical trial experience for diverse patient populations.

Female Leadership, Empowerment, and Self-Advocating Key to Overcoming Gender Inequities in Health Care

The vice president and chief pharmacy officer of City of Hope discusses obstacles women face in health care and how diversity, equity, and inclusion can be promoted within the space.

You Can Now Get Weight-Loss Drug Zepbound Through Amazon

Amazon Pharmacy will fill prescriptions ordered through Eli Lilly’s direct-to-consumer service.

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Lantern Pharma Inc. announced the dosing of the first two patients in the Phase 1 clinical trial evaluating Lantern’s investigational new drug LP-284 in patients with relapsed or refractory non-Hodgkin’s lymphoma, including mantle cell lymphoma and double hit lymphoma and other high-grade B-cell lymphomas as well as other select solid tumors and sarcomas.

@IQVIA_Institute on X:

The NIH Working Group on Global Health Research Equity Working Group’s highlights current initiatives and outlines next steps that NIH Institutes and Centers are taking to enable equitable research collaboration that is inclusive. #HealthEquity

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs

© 2024 MJH Life Sciences

All rights reserved.